For research use only. Not for therapeutic Use.
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research[1].
| Catalog Number | I043786 |
| CAS Number | 1952272-74-0 |
| Purity | ≥95% |
| Reference | [1]. Daniel Vt Catenacci, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-2082. |
